Aspen Pharmacare’s investment case is largely underpinned by the Group’s manufacturing facility

Aspen Pharmacare’s sterile manufacturing facility is expected to add R2bn from a contribution perspective in 2024 and R4bn in 2025 as the Group benefits from its significant manufacturing capacity. Aspen Pharmacare Group CEO Stephen Saad is in the C-SUITE and as upbeat as ever despite the tough operating environment that hit the group hard in it’s first half results reported earlier today .

Watch all our videos for In The C-Suite.